帕秦克隆
 | |
| 临床资料 | |
|---|---|
| 其他名称 | DN-2327 |
| ATC码 |
|
| 识别信息 | |
| |
| CAS号 | 103255-66-9  |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| 化学信息 | |
| 化学式 | C25H23ClN4O4 |
| 摩尔质量 | 478.93 g·mol−1 |
| 3D模型（JSmol） | |
| |
| |
帕秦克隆（英语：Pazinaclone，开发代号：DN-2327）是环吡咯酮类药物中的一种镇静剂和抗焦虑药。其他环吡咯酮药物包括佐匹克隆和右佐匹克隆。
帕秦克隆与苯二氮䓬类药物具有非常相似的药理学特性，包括镇静和抗焦虑特性，但遗忘作用较小，[1]并且在低剂量时它是一种相对选择性的抗焦虑药，而镇静作用仅在较高剂量时出现。[2]
帕秦克隆通过作为GABAA苯二氮䓬受体的部分激动剂发挥其镇静和抗焦虑作用，尽管帕秦克隆比大多数苯二氮䓬类药物更具亚型选择性。[3]
合成
7-氯-1,8-萘啶-2-胺与邻苯二甲酸酐反应生成相应的邻苯二甲酰亚胺。一个酰亚胺羰基的选择性还原实质上将其转化为醛。与三苯基磷乙酸叔丁酯的缩合得到维蒂希产物。
参见
- 帕戈克隆
参考资料
- ^ Wada T, Fukuda N. Effect of a new anxiolytic, DN-2327, on learning and memory in rats. Pharmacology, Biochemistry, and Behavior. March 1992, 41 (3): 573–9. PMID 1350101. S2CID 20581568. doi:10.1016/0091-3057(92)90375-p.
- ^ Suzuki M, Uchiumi M, Murasaki M. A comparative study of the psychological effects of DN-2327, a partial benzodiazepine agonist, and alprazolam. Psychopharmacology. October 1995, 121 (4): 442–50. PMID 8619007. S2CID 35222663. doi:10.1007/BF02246492.
- ^ Atack JR. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opinion on Investigational Drugs. May 2005, 14 (5): 601–18. PMID 15926867. S2CID 22793644. doi:10.1517/13543784.14.5.601.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
